AstraZeneca expects vaccine data this year, sales beat estimates

[FRANKFURT] AstraZeneca, the British drugmaker working on one of the world's leading Covid-19 vaccine candidates, on Thursday beat third-quarter sales estimates as demand for its diverse portfolio of drugs remained strong during Covid-19 pandemic lockdowns, and it maintained its 2020 forecasts.

The company reiterated it expected results from the late-stage trials on its experimental Covid-19 vaccine later this year, depending on the rate of infection among trial participants.

Product sales, which exclude payments from collaborations, rose 7 per cent to US$6.52 billion for the three months ended Sept 30 on a constant-currency basis, ahead of a company-compiled consensus of US$6.50 billion.

However, the company reported core earnings of 94 US cents per share, lower than analysts' expectations of 98 cents.

REUTERS

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL